更新高同型半胱氨酸血症降低治疗与心血管事件的关系。

Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events.

机构信息

Department of Cardiology, Second Affiliated Hospital, Nanchang University, Nanchang, China.

出版信息

Cardiovasc Ther. 2013 Aug;31(4):e19-26. doi: 10.1111/1755-5922.12014.

DOI:10.1111/1755-5922.12014

Abstract

Hyperhomocysteinemia (Hhcy) was defined as an independent risk factor for cardiovascular events. A number of clinical trials had investigated the relationship between Hhcy lowering treatment and cardiovascular diseases, however, the results of these studies remain controversial. This review article gave an over view of the homocysteine metabolisms and updated the recently published results in the role of Hhcy lowering therapy on cardiovascular events.

摘要

高同型半胱氨酸血症（HHcy）被定义为心血管事件的独立危险因素。许多临床试验已经研究了 HHcy 降低治疗与心血管疾病之间的关系，然而，这些研究的结果仍存在争议。本文综述了同型半胱氨酸代谢，并更新了最近发表的 HHcy 降低治疗对心血管事件作用的研究结果。